Jay Venkatesan
CIK 1413350 · See Remarks · last filed 2026-06-22
Jay Venkatesan is a corporate insider who has filed 54 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for SER, was dated Jun 22, 2026. Across all open-market trades the lifetime net is +$70.2K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.00M
8
54
$70.2K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SER | Director | 232,294 | $2.05 | $476.2K | $1.0K | 5 | 2026-06-22 |
| ELTX | Director | 180,534 | $2.89 | $521.7K | $0 | 6 | 2025-05-20 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 256,759 | $64.97 | $16.68M | -$2.74M | 11 | 2022-07-19 |
| Elicio Therapeutics, Inc. (ANGN) Delisted | See Remarks | 143,952 | $10.00 | $1.44M | -$3.95M | 10 | 2022-05-27 |
| XCUR | Director | 3,123 | $1.69 | $5.3K | $500.0K | 3 | 2020-07-08 |
| IOVANCE BIOTHERAPEUTICS, INC. (LBIO) Delisted | Director | — | — | — | $0 | 3 | 2017-06-05 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | EVP and General Manager | 4,076,723 | — | — | $500.0K | 7 | 2014-12-16 |
| Targanta Therapeutics Corp. (TARG) Delisted | Director | 2,092,987 | — | — | $5.75M | 2 | 2008-06-03 |
Recent Filings
54 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | SER | Mixed | +224,741 | $505.4K | EDGAR |
| 2026-04-21 | SER | Grant (A) | +7,553 | $14.7K | EDGAR |
| 2025-11-10 | SER | Grant (A) | — | $0 | EDGAR |
| 2025-05-20 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2025-04-10 | SER | Grant (A) | — | $0 | EDGAR |
| 2025-02-13 | SER | Grant (A) | — | $0 | EDGAR |
| 2025-01-02 | ELTX | Buy (P) | — | $0 | EDGAR |
| 2024-11-29 | ELTX | Exer (X) | +50,000 | $500 | EDGAR |
| 2024-11-25 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2024-07-02 | ELTX | Buy (P) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.